Ten Things You Might Not Know about Iron Oxide Nanoparticles

被引：140

作者：

Daldrup-Link, Heike E. ^{[1
,2
]}

机构：

[1] Stanford Univ, Lucile Packard Childrens Hosp, Dept Radiol, Dept Pediat,MIPS, 725 Welch Rd,Room 1665, Stanford, CA 94305 USA

[2] Stanford Univ, Lucile Packard Childrens Hosp, Inst Stem Cell Biol & Regenerat Med, 725 Welch Rd,Room 1665, Stanford, CA 94305 USA

来源：

RADIOLOGY | 2017年 / 284卷 / 03期

关键词：

ULTRASMALL SUPERPARAMAGNETIC PARTICLES; BLOOD-POOL AGENT; PROTEIN CORONA; CONTRAST AGENT; HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; COMPLEMENT ACTIVATION; YOUNG-ADULTS; HYPERSENSITIVITY REACTIONS; ATHEROSCLEROTIC PLAQUE;

D O I：

10.1148/radiol.2017162759

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Amid mounting concerns about nephrogenic sclerosis and gadolinium deposition in the brain, physicians and patients alike are starting to question the use of gadolinium chelates for clinical magnetic resonance (MR) imaging. The search for safer alternatives is currently underway. In North America, the iron supplement ferumoxytol has gained considerable interest as an MR contrast agent. In Europe, ferumoxtran-10 is entering phase III clinical trials. As these agents are starting to be used by a new generation of radiologists, important clinical questions have re-emerged, including those that have been answered in the past. This article offers 10 important insights for the use of iron oxide nanoparticles in clinical MR imaging. Published under a CC BY-NC-ND 4.0 license.

引用

页码：616 / 629

页数：14

共 113 条

[51] Rectal cancer: Mesorectal lymph nodes at MR Imaging with USPIO versus histopathologic findings - Initial observations [J].